NONMEM Users Network Archive

Hosted by Cognigen

RE: Pharmacoeconomic simulations

From: Jon Monteleone <jmonteleone>
Date: Thu, 30 Apr 2009 00:07:58 -0400

Peter,

 

Pharmacoeconomic means different things to different people, and the
following references should cover a useful spectrum

 

 

Poland B, Wada R. Combining drug-disease and economic modelling to
inform drug development decisions Drug Discovery Today. November
2001;6(22):1165-1170.

 

Korsan B, Dykstra K, Pullman W. Transparent Trade-Offs: A Clinical
Utility Index (CUI) Openly Evaluates a Product's Attributes - and Chance
of Success Pharmaceutical Executive. March 2005.

 

Poland B, Hodge F, Khan A, Clemen R, Dykstra K, Krishna R. The Clinical
Utility Index as a Practical Multiattribute Approach to Drug Development
Decisions (Accepted 2009)

 

Dykstra K, Hodge F, Carrothers TJ, Korsan B. Linking Modeling &
Simulation, Decision Analysis, and the Technology of Drug Formulation
American Conference on Pharmacometrics (ACoP); March 9-12, 2008; Tucson,
Arizona

 

Hodge F, Using the Clinical Utility Index (CUI) to Inform Dose Selection
Decisions; Webinar February 2009;
http://www.pharsight.com/events/eventsonline_archive.php#replay_028

 

Korsan B, Modeling and Decision Analysis to Support Formulation
Selection and Trial Sequencing, Webinar April 2006
http://www.pharsight.com/events/eventsonline_archive.php#replay_003

 

 

Cheers -Jon

 

________________________________

From: owner-nmusers
On Behalf Of jeffrey.a.wald
Sent: Thursday, April 23, 2009 4:39 PM
To: Bonate, Peter; nmusers
Subject: Re: [NMusers] Pharmacoeconomic simulations

 


A clinical utility index (CUI), as described recently by Ouellet et al.
Clinical Pharmacology & Therapeutics (2009); 85, 3, 277-282 as well as
by others elsewhere, is amenable to being used as a pharmacoeconomic
vehicle. Typically the CUI is derived in terms of patient benefit:risk,
but could easily be adapted to other tangible measures of value.

Jeff

 



"Bonate, Peter" <Peter.Bonate
Sent by: owner-nmusers

23-Apr-2009 10:37

        

To

nmusers

cc

 

Subject

[NMusers] Pharmacoeconomic simulations

 

 

 




Is anyone aware of any papers or abstracts using computer-assisted trial
design that incorporates a pharmacoeconomic component to the simulation?
Or any pop pharmacokinetic-pharmacodynamic papers that include the same?


Thanks

Pete bonate

Peter L. Bonate, PhD, FCP
Genzyme Corporation
Senior Director
Clinical Pharmacology and Pharmacokinetics
4545 Horizon Hill Blvd
San Antonio, TX 78229 USA
peter.bonate
phone: 210-949-8662
fax: 210-949-8219
crackberry: 210-315-2713
  
"Beware of geeks bearing formulas". Written by Warren Buffet as part of
Berkshire Hathaway's 2009 Annual Report to Stockholders.



image001.gif
(image/gif attachment: image001.gif)

Received on Thu Apr 30 2009 - 00:07:58 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: nmusers-request@iconplc.com.

Once subscribed, you may contribute to the discussion by emailing: nmusers@globomaxnm.com.